Cytarabine and Cisplatin as Salvage Therapy in Patients with Metastatic Colorectal Cancer Who Failed 5-Fluorouracil + Folinic Acid Regimen

Adenis, Antoine; Carlier, Damien; Darloy, Franck; Jm, Pion; Bonneterre, Jacques; Demaille, A

doi:10.1097/00000421-199504000-00013

Cited by 7 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the literature, Cytarabine has been studied in several cancers; however, a lack of information regarding this drug, speci cally in colon cancer, is observable. A combination of Cytarabine and cisplatin was utilized for metastatic colorectal patients who failed other chemotherapy agents [50].…”

Section: Detailed Investigation Over Obtained Drugsmentioning

confidence: 99%

Feature Selection and mRNA-miRNA bipartite Network Analysis for Biomarker Development and Drug Repurposing in Colon Cancer

Zavarzadeh,

Abedi,

Abbasi

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Colon cancer (CC) is the second cause of mortality among other non-skin cancers. Despite the progression in screening and diagnostic strategies, further information is still demanding for diagnosing, managing, and treating CC. In order to achieve this goal, computational analysis, including data mining algorithms are essential tools and the most widely used approach for achieving important features of gene expression data combined with clinical assessments which paves the way for diagnosis and treatment at the right time. Methods: This study aimed to identify the most critical genes and candidate drugs that may be helpful for CC treatment and develop novel microRNA biomarkers for CC. The gene expression data from CC tissues, including 98 CC and 98 normal samples, were used to reconstruct gene co-expression networks. Deferentially expressed genes (DEGs) were extracted after preprocessing and normalization. Then, DEGs were used to construct the weighted gene co-expression network (WGCNA), and low-preserved modules were obtained. The experimentally validated mRNA-miRNA interaction information was used to construct three bipartite mRNA-miRNA networks. From each bipartite network, ten hub miRNAs were extracted for further analysis. Finally, a drug-gene interaction network was constructed. Results: The most significant genes were ADH1B, AQP8, CA1, CLCA4, GUCA2B, MMP7, MS4A12, and TMIGD1 obtained from feature selection. The data included novel miRNAs (e.g., hsa-miR-665, hsa-miR-30c-3p, hsa-let-7b-5p, hsa-miR-3689d, hsa-miR-1233-5p, hsa-miR-1910-3p, and finally hsa-miR-6788-5p which was thoroughly novel without any investigation in other cancers) and might be potentially associated with CC. Also, the most important genes were targets for these miRNAs. Eventually, drugs such as Cytarabine, Levodopa, Methyldopa, Tretinoin, Hydralazine, Daunorubicin Hydrochloride, Olanzapine, and Idarubicin were proposed as potential novel drugs for CC treatment. Conclusion: The present study was performed to determine the most significant genes, develop biomarkers, and find novel potential drugs for colon cancer. All potential biomarkers and drugs obtained from this study could be practical after extensive experimental studies for using them in clinical experiments.

show abstract

Section: Detailed Investigation Over Obtained Drugsmentioning

confidence: 99%

Feature Selection and mRNA-miRNA bipartite Network Analysis for Biomarker Development and Drug Repurposing in Colon Cancer

Zavarzadeh,

Abedi,

Abbasi

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study

Lim

Park

et al. 2005

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

Our findings suggest that the combination of MMC and capecitabine in patients with advanced colorectal cancer pretreated with combination regimens including 5-FU, FA and CPT-11 or 5-FU, FA and L-OHP is safe. However, this regimen had a poor response rate and no definitive contribution to increasing patients' overall survival time. Further evaluation of other salvage regimens seems to be warranted.

show abstract

Zingerone protects against cisplatin-induced oxidative damage in the jejunum of Wistar rats

Rehman

Ahmad

et al. 2015

Orient Pharm Exp Med

View full text Add to dashboard Cite

Cytarabine and Cisplatin as Salvage Therapy in Patients with Metastatic Colorectal Cancer Who Failed 5-Fluorouracil + Folinic Acid Regimen

Cited by 7 publications

References 0 publications

Feature Selection and mRNA-miRNA bipartite Network Analysis for Biomarker Development and Drug Repurposing in Colon Cancer

Feature Selection and mRNA-miRNA bipartite Network Analysis for Biomarker Development and Drug Repurposing in Colon Cancer

Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study

Zingerone protects against cisplatin-induced oxidative damage in the jejunum of Wistar rats

Contact Info

Product

Resources

About